Skeptic critique for analysis AD-MASTER-PLAN-LRP1-20260428030757: AD Master Plan preregistration: LRP1
The analysis question is substantive, but the current record does not by itself prove the claim. The main dissent is: LRP1 has broad vascular and lipid roles, so blocking uptake may trade tau reduction for impaired clearance or vascular toxicity.
The debate should reject overclaiming in three forms. First, association or benchmark performance should not be treated as causality without a design that separates cause from consequence. Second, a positive average effect can hide subgroup failure across LRP1, AD, tau, amyloid. Third, an analysis that lacks provenance, environment capture, or preregistered endpoints can produce plausible but non-reproducible conclusions.
A decisive falsifier would be failure of cell-type-specific LRP1 perturbation with live tau uptake, trans-synaptic spread, and vascular safety readouts to move the predicted proximal endpoint under adequate power and controls. The strongest alternative explanation is that the observed signal is a disease-stage marker, prompt or notebook artifact, or compensatory response rather than an upstream driver.